

BILBIOGRAPHY

- Alakhali, K.M., Alshami, A.S., Al-dahbali, A.A., dan Khaled, S.F., 2024. antihypertensive agents in patients with Type 2 Diabetes patients visiting governmental hospital in Yemen Capital City. *Drug Discovery*, **18**.
- Ali, S., Hussain, R., Malik, R.A., Amin, R., dan Tariq, M.N., 2024. Association of Obesity With Type 2 Diabetes Mellitus: A Hospital-Based Unmatched Case-Control Study. *Cureus*, **16**: 1–7.
- Alsaadon, H., Afroz, A., Karim, A., Habib, S.H., Alramadan, M.J., Billah, B., et al., 2022. Hypertension and its related factors among patients with type 2 diabetes mellitus – a multi-hospital study in Bangladesh. *BMC Public Health*, **22**: 198.
- Al-Saleh, Y., Sabico, S., Al-Furqani, A., Jayyousi, A., Alromaihi, D., Ba-Essa, E., et al., 2021. Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas. *Diabetes Therapy*, **12**: 2115–2132.
- Altuntaş, Y., 2019. Approach to the treatment of diabetes in the elderly. *SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital*, **53**: 96–102.
- Ambrož, M., Geelink, M., Smits, K.P.J., De Vries, S.T., dan Denig, P., 2023. Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care. *Diabetic Medicine*, **40**: 1–10.
- Apriliany, F., Cholisah, E., dan Erlianti, K., 2022. Efek Pemberian Metformin dan Metformin+Glimepiride terhadap Kadar HbA1c pada Pasien Diabetes Mellitus Tipe 2. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, **12**: 97.
- Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., dan Rasouli, N., 2021. Should metformin remain the first-line therapy for treatment of type 2 diabetes? *Therapeutic Advances in Endocrinology and Metabolism*, **12**.
- Butt, M.D., Ong, S.C., Wahab, M.U., Rasool, M.F., Saleem, F., Hashmi, A., et al., 2022. Cost of Illness Analysis of Type 2 Diabetes Mellitus: The Findings

from a Lower-Middle Income Country. *International Journal of Environmental Research and Public Health*, **19**: 12611.

Cho, Y.Y., and Cho, S., 2021. Treatment Variation Related to Comorbidity and Complications in Type 2 Diabetes Mellitus. *Medicine*. **2018**:1-7.

Choi, J.H., Lee, K.A., Moon, J.H., Chon, S., Kim, D.J. Kim, H.J., et al. 2023. 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. *Diabetes & Metabolism Journal*. **47**: 575-594.

Ciarambino, T., Crispino, P., Leto, G., Mastrolorenzo, E., Para, O., dan Giordano, M., 2022a. Influence of Gender in Diabetes Mellitus and Its Complication. *International Journal of Molecular Sciences*, **23**: 8850.

Ciarambino, T., Crispino, P., Leto, G., Mastrolorenzo, E., Para, O., dan Giordano, M., 2022b. Influence of Gender in Diabetes Mellitus and Its Complication. *International Journal of Molecular Sciences*, **23**: 1–13.

Dahlan, S., 2009. *Statistik untuk Kedokteran dan Kesehatan*, 4th ed. Salemba Medika, Jakarta.

Doucet, J., Gourdy, P., Meyer, L., Benabdelmoumene, N., Bourden-Marchasson, I., 2023. Management of Glucose-Lowering Therapy in Older Adults with Type 2 Diabetes: Challenges and Opportunities. *Clinical Interventions in Aging*, **18**: 1687-1703.

Du, G., Xie, W., Su, Y., Ma, Y., Gao, X., Jiang, S., et al., 2020. Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study. *PeerJ*, **8**: e9905.

Eltaib, L., Department of Pharmaceutics, Faculty of Pharmacy, Northern Border University, Arar, Saudi Arabia, M. Alenzi, S., dan Department of Pharmacy, Northern Area Armed Forces Hospital, Saudi Arabia, 2020. Comparative Efficacy of Metformin and Sulfonylurea in Monotherapy or Combination for Type 2 Diabetes Mellitus. *Asian Journal of Pharmaceutical Research and Health Care*, **12**: 223–233.

- Fitria, N., Anggraini, L.F., dan Sari, Y.O., 2023. Cost-Effectiveness Analysis of the Combination of Metformin-Insulin Glargine and Metformin-Glimepiride in Type 2 Diabetes Mellitus Patients in Rupit Hospital **1**.
- Galicía-García, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., et al., 2020. Pathophysiology of Type 2 Diabetes Mellitus. *International Journal of Molecular Sciences*, **21**: 6275.
- Garber, A.J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M.J., Barzilay, J.I., et al., 2020. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. *Endocrine Practice*, **26**: 107–139.
- Gebrie, D., Manyazewal, T., Ejigu, D.A., dan Makonnen, E., 2021a. Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **Volume 14**: 3345–3359.
- Gebrie, D., Manyazewal, T., Ejigu, D.A., dan Makonnen, E., 2021b. Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **14**: 3345–3359.
- Gilmer, T.P., O'Connor, P.J., Rush, W.A., Crain, A.L., Whitebird, R.R., Hanson, A.M., et al., 2005. Predictors of Health Care Costs in Adults With Diabetes. *Diabetes Care*, **28**: 59–64.
- Gu, S., Shi, L., Shao, H., Wang, X., Hu, X., Gu, Y., et al., 2020. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. *BMC Medicine*, **18**: 378.
- Hadiq, S., Supadmi, W., dan Perwitasari, D.A., 2022. Cost-effectiveness analysis of metformin and metformin- glimepiride in patients with type 2 diabetes at Nene Mallomo General Hospital, Sidenrang Rappang **19**.

- Hardianto, D., 2021. Insulin: Produksi, Jenis, Analisis, Dan Rute Pemberian. *Jurnal Bioteknologi dan Biosains Indonesia*, **8**.
- Hidayat, B., Ramadani, R.V., Rudijanto, A., Soewondo, P., Suastika, K., dan Siu Ng, J.Y., 2022. Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia. *Value in Health Regional Issues*, **28**: 82–89.
- Hosseinipoor, H., Kariminejad, S.Y., Salehi, M., Heidari, M., Goodarzi, M.T., dan Karimi, M.H., 2022. The effects of metformin monotherapy and combination of metformin and glibenclamide therapy on the expression of RAGE, Sirt1, and Nrf2 genes in peripheral blood mononuclear cells of type 2 diabetic patients. *Journal of Diabetes & Metabolic Disorders*, **21**: 369–377.
- Hurst, C., Thinkhamrop, B., dan Tran, H.T., 2015. The Association between Hypertension Comorbidity and Microvascular Complications in Type 2 Diabetes Patients: A Nationwide Cross-Sectional Study in Thailand. *Diabetes & Metabolism Journal*, **39**: 395–404.
- Hussain, S. dan Chowdhury, T.A., 2019. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. *Drugs*, **79**: 231–242.
- Hyun, M.K., Park, J.H., Kim, K.H., Ahn, S.-K., dan Ji, S.M., 2021. Incidence and Risk Factors for Progression to Diabetes Mellitus: A Retrospective Cohort Study. *International Journal of Environmental Research and Public Health*, **19**: 123.
- Ismail, L., Materwala, H., dan Al Kaabi, J., 2021. Association of risk factors with type 2 diabetes: A systematic review. *Computational and Structural Biotechnology Journal*, **19**: 1759–1785.
- Jadhav, N.B., Bhosale, M.S., dan Adhav, C.V., 2013. Cost Analysis Study of Oral Antidiabetic Drugs Available in Indian Market. *International Journal of Medical Research & Health Sciences*, **2**: 63–69.
- Jia, G. dan Sowers, J.R., 2021. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. *Hypertension*, **78**: 1197–1205.

- Jimeno, C., Sy, R.A., De La Pena, P., Cipriano, C., Tan, R., Pabello, A., et al., 2021. Direct medical costs of type 2 diabetes mellitus in the Philippines: findings from two hospital databases and physician surveys. *BMJ Open*, **11**: 1–10.
- Joshi, S.R., Ramachandran, A., Chadha, M., Chatterjee, S., Rathod, R., dan Kalra, S., 2014. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes. *Expert Opinion on Pharmacotherapy*, **15**: 1611–1620.
- Kalra, S., Das, A., Priya, G., Ghosh, S., Mehrotra, R., Das, S., et al., 2020. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. *Journal of Family Medicine and Primary Care*, **9**: 5450.
- Kamangar, F. 2012. Confounding Variables in Epidemiologic Studies: Basics and Beyond. *Archives of Iranian Medicine*. **15(8)**: 508-516.
- Kautzky-Willer, A., Leutner, M., dan Harreiter, J., 2023. Sex differences in type 2 diabetes. *Diabetologia*, **66**: 986–1002.
- Ke, C., Narayan, K.M.V., Chan, J.C.N., Jha, P., dan Shah, B.R., 2022. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. *Nature Reviews Endocrinology*, **18**: 413–432.
- Kementerian Kesehatan Indonesia, 2020. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/603/2020. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan Republik Indonesia, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan Republik Indonesia, Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kementerian Keuangan, 2023. Peraturan Menteri Keuangan Republik Indonesia Nomor 31 TAHUN 2023 TENTANG Tarif Layanan Badan Layanan Umum Rumah Sakit Tingkat II, Tingkat III, dan Tingkat IV pada Kementerian Pertahanan.
- Kim, J.Y. dan Kim, N.H., 2023. Initial Combination Therapy in Type 2 Diabetes. *Endocrinology and Metabolism*. **8**.

- Kristanti, D., Rahajeng, E., Sulistiowati, E., Kusumawardani, N., dan Dany, F., 2021. Determinants of diabetes comorbidities in Indonesia: a cohort study of non-communicable disease risk factor. *Universa Medicina*, **40**: 3–13.
- Kristina, Dwi Endarti, Tri Murti Andayani, dan Anna Wahyuni, 2020. Direct and Indirect Cost of Diabetes Mellitus in Indonesia: A Prevalence Based Study with Human Capital Approach. *International Journal of Pharmaceutical Research*, **13**.
- Kumar, S., 2015. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus. *Journal Of Clinical And Diagnostic Research*. **8**.
- Kurniawan, A.H. dan Fauzan, M.N., 2022. Treatment Pattern And Cost-Effectiveness Analysis Of Oral Hypoglycemics For Type 2 Diabetes Mellitus Outpatients At Regional General Hospital, Indonesia. *Malaysian Journal of Public Health Medicine* **22**.
- Laelasari, E., Sauriasari, R., dan Banun, A., 2017. Cost-Effectiveness Analysis Of Insulin, Sulfonylurea, And Sulfonylurea– Metformin In Type 2 Diabetes Mellitus. *Asian Journal of Pharmaceutical and Clinical Research*, **10**: 50.
- Lam, A.A., Lepe, A., Wild, S.H., dan Jackson, C., 2021. Diabetes comorbidities in low- and middle-income countries: An umbrella review. *Journal of Global Health*, **11**: 04–14.
- Lemeshow, S., Hosmer Jr, D.W., Klar, J., dan Lwanga, S.K., 1990. *Adequacy of Sample Size in Health Studies*. John Wiley & Sons Ltd, England.
- Lim, P.C. dan Chong, C.P., 2015. What's next after metformin? focus on sulphonylurea: add-on or combination therapy. *Pharmacy Practice*, **13**: 606–606.
- Liu, Z., Zhao, X., Sun, W., Wang, Y., Liu, S., dan Kang, L., 2017. Metformin combined with acarbose vs. single medicine in the treatment of type 2 diabetes: A meta-analysis. *Experimental and Therapeutic Medicine*, **13**: 3137–3145.
- Lorenzoni, V., Baccetti, F., Genovese, S., Torre, E., dan Turchetti, G., 2017. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy

for the treatment of diabetic patients in Italy. *ClinicoEconomics and Outcomes Research*, **9**: 699–710.

McClever, Lindsey.A., Preuss, C.V., dan Trip, J., 2022. Acarbose. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK493214/>. Accessed at Februari, 2024.

Mohan, V., Saboo, B., Khader, J., Modi, K.D., Jindal, S., Wangnoo, S.K., et al., n.d. Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines. *Endocrinology and Diabetes*. **15**: 1-8.

Moon, M.K., Hur, K.-Y., Ko, S.-H., Park, S.-O., Lee, B.-W., Kim, J.H., et al., 2017. Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. *Diabetes & Metabolism Journal*, **41**: 357.

Mursalin, M. dan Soewondo, P., 2017. Analisis Estimasi Biaya Langsung Medis Penderita Rawat Jalan Diabetes Mellitus Tipe 2 di RSUD Dr. Abdul Aziz Singkawang Tahun 2013. *Jurnal Ekonomi Kesehatan Indonesia*, **1**: 1–12.

Naseri, M.W., Esmat, H.A., dan Bahee, M.D., 2022. Prevalence of hypertension in Type-2 diabetes mellitus. *Annals of Medicine & Surgery*, **78**: 1–4.

Nurhasanah, R., Khairunnisa, and Harahap, U., 2021. Potential Drug Interactions of Oral Antidiabetic in Prescriptions of Type 2 Diabetes Mellitus Patients at Kumpulan Pane Hospital. *International Journal of Science, Technology & Management*. **1**.

Ong, K.L., Stafford, L.K., McLaughlin, S.A., Boyko, E.J., Vollset, S.E., Smith, A.E., et al., 2023. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet*, **402**: 203–234.

Ono, R., Ogami, C., Hasegawa, C., To, H., Matsumoto, Y., dan Tsuji, Y., 2023. Comparison of the efficacy of anti-diabetic medications as add-on to metformin in type 2 diabetes mellitus from a real-world database. *BMC Pharmacology and Toxicology*, **24**: 75.

Ou, H.-T., Chen, Y.-T., Liu, Y.-M., dan Wu, J.-S., 2016. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes:

- Evidence from a population-based national cohort in Taiwan. *Diabetes Research and Clinical Practice*, **116**: 14–25.
- Pambagyanik, A.A., Lorensia, A., dan Rahem, A., 2023. Analisis Cost-Effectiveness Kombinasi Glimepiride-Metformin Dengan Glimepiride-Pioglitazone pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan. *MPI (Media Pharmaceutica Indonesiana)*, **5**: 107–116.
- Pathan, S., Piemonte, L., Malanda, B., dan Savuleac, R., 2017. *Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care*. IDF Executive Office - Belgium.
- Patty, Y.F.P.P., Nita, Y., dan Libriansyah, 2022. Cost of illness analysis of diabetes mellitus with complications in one hospital in Surabaya. *Pharmacy Education*, **22**: 254–258.
- Perkumpulan Endokrinologi Indonesia, 2021. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia. Jakarta: PB. PERKENI.
- Rascati, K.L., 2012. *Essential of Pharmacoeconomics*, 2nd ed. Wolters Kluwer Health, Texas.
- Rhee, M.K., Ho, Y.-L., Raghavan, S., Vassy, J.L., Cho, K., Gagnon, D., et al., 2019. Random plasma glucose predicts the diagnosis of diabetes. *PLOS ONE*, **14**.
- Sahay, R.K., Mittal, V., Gopal, G.R., Kota, S., Goyal, G., Abhyankar, M., et al., 2020. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence. *Cureus*. **12(9)**.
- Samson, S.L., Vellanki, P., Blonde, L., Christofides E.A., Galindo, R.J., Hirsch, I.B., et al., 2023. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. *Endocrine Practice*. **29**: 305-340.
- Seuring, T., Archangelidi, O., dan Suhrcke, M., 2015. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. *Pharmacoeconomics*, **33**: 811–831.

- Stephens, J., Anderson, R., dan Hayes, J., 2016. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. *Drug Design, Development and Therapy*, **10**: 2263–2270.
- Sylvia, S., Sauriasari, R., dan Andrajati, R., 2018. Comparison of Insulin, Sulfonylurea and Sulfonylureas-Metformin Combination on HbA1c and eGFR Level on Age-, Sex- and BMI-Matched Groups of Indonesian Type 2 DM Patients. *Journal of Young Pharmacists*, **10**: 471–475.
- Tandon, T., Dubey, A., Srivastava, S., Manocha, S., Arora, E., dan Hasan, N., 2019. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. *Journal of Family Medicine and Primary Care*, **8**: 955.
- Tosur, M., Viau-Colinders, J., Astudillo, M., Redondo, M.J., and Lyons, S.K., 2019. Medication-induced Hyperglycemia: Pediatric Perspective. *Diabetes Research & Care*. **8**.
- Wang W., Fu, C., Zhuo H., Luo J., and Xu, B., 2010. Factors Affecting Costs and Utilization of Type 2 Diabetes Healthcare: A Cross-sectional Survey among 15 Hospitals in Urban China. *BMC Health Service Research*. **10**:244.
- Wang, J.-S., Huang, C.-N., Hung, Y.-J., Kwok, C.-F., Sun, J.-H., Pei, D., et al., 2013. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. *Diabetes Research and Clinical Practice*, **102**: 16–24.
- Wikannanda, I.A.A.D., Sari, N.L.P.E.K., dan Aryastuti, A.A.S.A., 2023. Gambaran Penggunaan Terapi Kombinasi Oral Metformin-Sulfonilurea pada Pasien DM Tipe 2 di Denpasar. *AMJ (Aesculapius Medical Journal)*, **3**: 224–232.
- World Health Organization, 2019. *Classification of Diabetes Mellitus*. World Health Organization, Geneva.
- Wulandari, N., Maifitrianti, M., Muthi'ah, F., dan Disya, N.N., 2021. Antidiabetic Regimen and Factors Associated with Glycemic Control in Patients with Type 2 Diabetes mellitus in Public Health Centers in Jakarta: A Cross-

Sectional Study. *Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **11**: 164.

Wuryandari, H., Raising, R., dan Widiarini, R., 2021. Analisis Efektivitas Biaya Terapi Antidiabetes Oral Kombinasi Pada Pasien Diabetes Melitus Tipe 2 Di Rsud Kota Madiun Tahun 2020. *Duta Pharma Journal*, **1**: 1–7.

Yakaryılmaz, F.D. dan Öztürk, Z.A., 2017. Treatment of type 2 diabetes mellitus in the elderly. *World Journal of Diabetes*, **8**: 278.

Yang, H.K., Lee, S.-H., Shin, J., Choi, Y.-H., Ahn, Y.-B., Lee, B.-W., et al., 2019. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. *Diabetes & Metabolism Journal*, **43**: 287.

Zhu, J., Zhou, Y., Li, Q., dan Wang, G., 2023. Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review. *Advances in Therapy*, **40**: 4216–4235.